← ANALYST RATINGS · TIPRANKS
Relmada Therapeutics (RLMD): analyst forecast and price target
Analyst consensus
Moderate Buy2 Buy0 Hold0 Sell
Ratings of 2 analysts in the last 3 months · top analysts only12-month forecast
Based on 2 price targets given in the last 3 months, the average target is $12.00, the highest $12.00, the lowest $12.00. The average is +287.1% from the last price of $3.10.
Analyst ratings 5
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $3.50 → $3.00−14.3% | Hold | −3.2% | Reiterated | 17.10.26on TipRanks Oct 16 21:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $3.50 → $3.00−14.3% | Hold | −3.2% | Reiterated | 15.10.26on TipRanks 16:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $3.50 → $3.00−14.3% | Hold | −3.2% | Reiterated | 15.10.26on TipRanks 16:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $3.50 → $3.00−14.3% | Hold | −3.2% | Reiterated | 15.10.26on TipRanks 16:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $3.50 → $3.00−14.3% | Hold | −3.2% | Reiterated | 15.10.26on TipRanks 16:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $3.00 → $3.50+16.7% | Hold | +12.9% | Reiterated | 11.10.26on TipRanks 19:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $3.00 → $3.50+16.7% | Hold | +12.9% | Reiterated | 11.10.26on TipRanks 19:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $3.00 → $3.50+16.7% | Hold | +12.9% | Reiterated | 11.10.26on TipRanks 19:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $3.00 → $3.50+16.7% | Hold | +12.9% | Reiterated | 11.10.26on TipRanks 19:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $3.00 → $3.50+16.7% | Hold | +12.9% | Reiterated | 11.10.26on TipRanks 19:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $3.00 → $3.50+16.7% | Hold | +12.9% | Reiterated | 11.10.26on TipRanks 19:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $3.50 → $3.00−14.3% | Hold | −3.2% | Reiterated | 09.10.26on TipRanks 11:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $3.50 → $3.00−14.3% | Hold | −3.2% | Reiterated | 09.10.26on TipRanks 11:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $3.50 → $3.00−14.3% | Hold | −3.2% | Reiterated | 08.10.26on TipRanks 07:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $3.50 → $3.00−14.3% | Hold | −3.2% | Reiterated | 07.10.26on TipRanks 05:06 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $3.50 → $3.00−14.3% | Hold | −3.2% | Reiterated | 07.10.26on TipRanks 05:06 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $3.50 → $3.00−14.3% | Hold | −3.2% | Reiterated | 07.10.26on TipRanks 05:06 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $4.00 → $3.50−12.5% | Hold | +12.9% | Reiterated | 02.10.26on TipRanks 19:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $4.00 → $3.50−12.5% | Hold | +12.9% | Reiterated | 02.10.26on TipRanks 19:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $4.00 → $3.50−12.5% | Hold | +12.9% | Reiterated | 02.10.26on TipRanks 19:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $3.50 → $4.00+14.3% | Hold | +29.0% | Reiterated | 01.10.26on TipRanks 17:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $4.00 | Hold | +29.0% | Reiterated | 30.09.26on TipRanks 16:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $3.50 | Hold | +12.9% | Reiterated | 30.09.26on TipRanks 16:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $4.00 → $3.50−12.5% | Hold | +12.9% | Reiterated | 30.09.26on TipRanks 16:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $3.50 | Hold | +12.9% | Reiterated | 30.09.26on TipRanks 16:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $4.00 | Hold | +29.0% | Reiterated | 30.09.26on TipRanks 16:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $4.00 → $3.50−12.5% | Hold | +12.9% | Reiterated | 30.09.26on TipRanks 16:05 | — | |
| Andres Y. Maldonado★★★★★★★★★★#149 · hits 58% · avg +42.1% | H.C. Wainwright | $12.00 | Buy | +287.1% | Reiterated | 10.08.26on TipRanks Aug 7 09:55 | −8.6%next day −8.1% · 5 days −3.2% | ↗ |
| Kelsey Goodwin★★★★★★★★★★#203 · hits 68% · avg +62.4% | Piper Sandler | $12.00 | Buy | +287.1% | Reiterated | 07.08.26on TipRanks 11:27 | −8.6%next day −8.1% · 5 days −3.2% | ↗ |
| Christopher Liu★★★★★★★★★★#2941 · hits 44% · avg +8.9% | Lucid Capital | $14.00 | Buy | +351.6% | Initiated | 02.03.26on TipRanks 06:40 | +6.1%next day −2.6% · 5 days +49.3% | ↗ |
| Andrew Berens★★★★★★★★★★#336 · hits 49% · avg +24.7% | Leerink Partners | $8.00 | Buy | +158.1% | Initiated | 23.01.26on TipRanks 06:30 | −1.6%next day +1.3% · 5 days −9.4% | ↗ |
| Farzin Haque★★★★★★★★★★#6078 · hits 55% · avg +7.3% | Jefferies | $9.00 | Buy | +190.3% | Initiated | 21.12.25on TipRanks 19:05 | +2.6%next day −0.5% · 5 days +0.6% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Relmada Therapeutics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $12.00 at a price of $3.77 (+218.3%); now: $12.00 at $3.10 (+287.1%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 5 | 5 | 6 | 4 | 3 |
| Buy | 1 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 05.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.14 (from $-0.16 to $-0.14). Last quarter: $-0.11.
Best top-analyst consensus in the sector · Healthcare
About Relmada Therapeutics
- CEO: Sergio Traversa
- Employees: 17
- 2222 Ponce de Leon Blvd., Coral Gables, FL, 33134, US
- www.relmada.com
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
Data from the stock’s TipRanks forecast page, read 195 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗